SRXHConsumer Defensive · Packaged Foods

SRXH Stock Forecast: SRX Global, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$1.59

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$32.2M

Ticker Nerd rank

3 / 100

Median analyst target

—

Analysts covering

—

Revenue$3.4M

Operating income−$3.2M

Net income−$4.1M

Free cash flow−$956K

Quarterly, 7 quarters to 30 June 2026 · latest quarter's figure shown

Ticker Nerd rank

SRXH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SRX Global, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Issuance

Volatility

Momentum

Accruals

Quality

Value

Growth

Size (86): Smaller than most of the companies we track.

Growth (1): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRXH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRXH, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRXH appears on the weeks it earns a place.

Estimates

SRXH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

SRX Global, Inc. (SRXH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.0×
Price / sales: 4.9×
Price / book: 0.5×
EV / EBITDA: 1.2×

Growth & margins

Revenue growth (YoY): −1.4%
Earnings growth (YoY): −52.0%
Gross margin: 26.7%
Operating margin: −94.4%
Net margin: 23.4%

Returns & dividend

Return on equity: −11058.0%
Return on assets: −535.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SRX Global, Inc. (SRXH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

SRX Global, Inc. has a market value of $32.2M and an enterprise value of −$14.0M.
Revenue in the twelve months to 30 June 2026: −$24.9M. The latest quarter shrank 1.4% year on year.
Net income over the same four quarters: −$34.4M, a 138.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$2.9M.
Shares outstanding: 14.3M.
Trailing P/E: −0.0×.
SRX Global, Inc. employs 7 people — −$3.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SRXH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaged Foods

Company	Market cap	TKN rank
SRXHSRX Global, Inc.	$32.2M	3
BRLSBorealis Foods, Inc.	$30.0M	47
BHSTBioHarvest Sciences, Inc.	$40.8M	42
COOTAustralian Oilseeds Holdings Ltd.	$22.4M	7
LSFLaird Superfood, Inc.	$43.1M	22
JVACoffee Holding Co., Inc.	$22.0M	95
CLNNClene, Inc.	$45.6M	27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SRX Global, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRXH news & analysis

SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company

GlobeNewsWire · 3 Sept 2026positive

SRX Global issued a shareholder update on its portfolio company ARMR Sciences, a clinical-stage biodefense firm developing medical countermeasures against synthetic drugs such as fentanyl. The update, led by ARMR's CEO Collin Gage, provides information on the portfolio company's progress to shareholders.

Why it matters — The update offers SRXH watchers insight into the development status of ARMR Sciences, a portfolio company that represents part of SRX Global's investment strategy.

SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers

GlobeNewsWire · 31 Aug 2026neutral

SRX Global, Inc. has acquired senior secured debt in CERo Therapeutics Holdings, Inc., a cellular immunotherapy company developing a cancer-fighting molecule for hematologic cancers. The debt investment is expected to accelerate development of CERo's lead therapeutic candidate, CER-1236.

Why it matters — SRXH watchers would care because this acquisition expands SRX Global's investment portfolio into the cellular immunotherapy sector, potentially positioning the company in the oncology development space.

SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results

GlobeNewsWire · 13 Aug 2026positive

SRX Global Inc. announced its fiscal third quarter 2026 financial results, reporting a Net Asset Value of $62.9 million ($3.22 per share), exceeding its preliminary estimate, with no debt outstanding and an improved Adjusted EBITDA loss.

Why it matters — The company reported stronger-than-expected NAV per share, improved operational performance with 98% fill rates at Halo, and a 35% year-over-year improvement in Adjusted EBITDA loss, indicating financial progress.

SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET

GlobeNewsWire · 6 Aug 2026neutral

SRX Global, Inc. (NYSE American: SRXH) announced it will host a conference call and report its financial results for the fiscal third quarter ended June 30, 2026, on Thursday, August 13, 2026, at 4:30 p.m. ET.

Why it matters — SRXH watchers will be able to hear the company's fiscal third-quarter results and commentary directly from management on the scheduled call.

SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)

GlobeNewsWire · 4 Aug 2026positive

SRX Global, Inc. announced it has acquired a stake in Vistagen Therapeutics, a late clinical-stage biopharmaceutical company developing intranasal neuroscience product candidates called pherines. The investment adds Vistagen to SRX's holdings of operating companies and strategic assets.

Why it matters — SRXH watchers would care because the acquisition expands SRX's investment portfolio with a stake in a late-stage biopharmaceutical company focused on neuroscience drug development.

FAQ

Frequently asked questions about SRXH stock

How does Ticker Nerd's model rank SRXH?

As at 12 Sept 2026, SRX Global, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

What is the SRXH stock forecast for 2030?

No analyst covering SRX Global, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRXH are extrapolating price history, which says nothing about the business.

What does SRX Global, Inc. do?

SRx Health Solutions Inc. is a healthcare services company focused on specialty pharmacy care, clinic services, and patient support across Canada.

What is the latest news on SRXH?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company". SRX Global issued a shareholder update on its portfolio company ARMR Sciences, a clinical-stage biodefense firm developing medical countermeasures against synthetic drugs such as fentanyl. The update, led by ARMR's CEO Collin Gage, provides information on the portfolio company's progress to shareholders.

Company

About SRX Global, Inc.

SRx Health Solutions Inc. is a healthcare services company focused on specialty pharmacy care, clinic services, and patient support across Canada. The company operates an integrated network that includes specialty pharmacies, infusion and injection clinics, clinical trial sites, pharmacy wholesale and distribution, nursing services, and allied health support. Its offerings cover medication management, vaccination services, compounding, diabetes care, travel health, and other specialized treatment programs designed to support patients with complex or ongoing needs. SRx Health Solutions also serves healthcare providers and institutions through collaborative service models that connect pharmacies, clinics, and support programs. In addition, the company operates a pet health and wellness business under the Halo brand, offering foods, treats, chews, dental products, and supplements for dogs and cats. The business plays a role in specialty healthcare delivery by combining clinical services, pharmaceutical operations, and wellness products in one platform.

CEO Dr. Eric M. Jackson Ph.D. · 7 employees · United States · https://www.srxglobalinc.com